NMRD — Nemaura Medical Share Price
0.000.00%
Last trade - 00:00- $1.57m
- $21.07m
- $0.08m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 0.5 | 0.08 | 0.2 | 1.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
Directors
- Dewan Chowdhury CHM (48)
- Justin Mclarney CFO (49)
- Arash Ghadar COO (45)
- Bashir Timol DRC (46)
- Timothy Johnson IND (37)
- Thomas Moore IND (57)
- Salim Natha IND (54)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 24th, 2013
- Public Since
- November 4th, 2014
- No. of Shareholders
- 80
- No. of Employees
- 36
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 28,899,402
- Address
- 57 W 57th St, NEW YORK, 10019-2802
- Web
- https://nemauramedical.com/
- Phone
- +44 1509222912
- Auditors
- WEINBERG & COMPANY PA
Upcoming Events for NMRD
Q1 2025 Nemaura Medical Inc Earnings Release
Similar to NMRD
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
What is the Nemaura Medical share price?
As of Today at 19:15 UTC, shares in Nemaura Medical are trading at $0.05. This share price information is delayed by 15 minutes.
How has the Nemaura Medical share price performed this year?
Shares in Nemaura Medical last closed at $0.05 and the price had moved by -92.83% over the past 365 days. In terms of relative price strength the Nemaura Medical share price has underperformed the S&P500 Index by -93.81% over the past year.
What are the analyst and broker recommendations for Nemaura Medical?
The overall consensus recommendation for Nemaura Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nemaura Medical dividend yield?
Nemaura Medical does not currently pay a dividend.
Does Nemaura Medical pay a dividend?
Nemaura Medical does not currently pay a dividend.
When does Nemaura Medical next pay dividends?
Nemaura Medical does not currently pay a dividend.
How do I buy Nemaura Medical shares?
To buy shares in Nemaura Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nemaura Medical?
As of the previous close price of $0.05, shares in Nemaura Medical had a market capitalisation of $1.57m.
Where are Nemaura Medical shares listed?
Here are the trading details for Nemaura Medical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NMRD
What kind of share is Nemaura Medical?
Based on an overall assessment of its quality, value and momentum Nemaura Medical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nemaura Medical share price forecast for 2024?
The analyst consensus target price for shares in Nemaura Medical is $1.50. That is 2667.53% above the last closing price of $0.05.
Analysts covering Nemaura Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.32 for the next financial year.
What is the trend in the Nemaura Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nemaura Medical. Over the past six months, its share price has underperformed the S&P500 Index by -82.98%.
As of the last closing price of $0.05, shares in Nemaura Medical were trading -81.38% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nemaura Medical PE Ratio?
The Nemaura Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nemaura Medical?
Nemaura Medical's management team is headed by:
- Dewan Chowdhury - CHM
- Justin Mclarney - CFO
- Arash Ghadar - COO
- Bashir Timol - DRC
- Timothy Johnson - IND
- Thomas Moore - IND
- Salim Natha - IND